SEC Contract Filing

Filing Date: 2017-04-26

Document Content:
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>5
<FILENAME>bpmx-20170426ex102ab73eb.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!--HTML document created with Merrill Bridge 7.0.61.0-->
<!--Created on: 4/26/2017 4:13:17 PM-->
<html>
	<head>
 <title>
 bpmx_Ex10_2
 </title>
	</head>
	<body><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;"><div style="width:100%">

 <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

 <font style="display:inline;"><img src="bpmx20170426ex102ab73eb001.jpg" style="width: 2.8125in; height: 0.6458333in" alt="Picture 2"></font>

 </p>

</div></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;">
 <p style="margin:0pt 0pt 18pt 252pt;text-indent:36pt;text-align:right;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;">
 <font style="display:inline;font-weight:bold;">Exhibit 10.2</font>
 </p>
 <p style="margin:0pt 0pt 18pt 252pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;">
 <font style="display:inline;">April 26, 2017</font>
 </p>
 <p style="margin:0pt 0pt 18pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
 <font style="display:inline;font-weight:bold;font-size:12pt;text-decoration:underline;">CONFIDENTIAL</font>
 </p>
 <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
 <font style="display:inline;font-size:12pt;">Ms. Anja Krammer</font>
 </p>
 <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
 <font style="display:inline;font-size:12pt;">President</font>
 </p>
 <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
 <font style="display:inline;font-size:12pt;">BioPharmX Corporation</font>
 </p>
 <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
 <font style="display:inline;font-size:12pt;">1098 Hamilton Court</font>
 </p>
 <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
 <font style="display:inline;font-size:12pt;">Menlo Park, CA 94025</font>
 </p>
 <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
 <font style="display:inline;font-size:12pt;">&nbsp;</font>
 </p>
 <p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
 <font style="display:inline;font-size:12pt;">Re:<font style="display:inline;font-size:12pt;;font-size: 12pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font>Engagement of Roth Capital Partners, LLC as advisors to BioPharmX Corporation</font>
 </p>
 <p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
 <font style="display:inline;font-size:12pt;">Dear Ms. Krammer:</font>
 </p>
 <p style="margin:0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
 <font style="display:inline;font-size:12pt;">This letter will confirm our understanding that BioPharmX Corporation (the &#x201C;</font><font style="display:inline;font-size:12pt;text-decoration:underline;">Company</font><font style="display:inline;font-size:12pt;">&#x201D;) has engaged Roth Capital Partners, LLC (&#x201C;</font><font style="display:inline;font-size:12pt;text-decoration:underline;">Roth</font><font style="display:inline;font-size:12pt;">&#x201D;) to act as the Company&#x2019;s exclusive placement agent or sole book running manager in connection with the matters described below, subject to the terms and conditions of this letter agreement (this &#x201C;</font><font style="display:inline;font-size:12pt;text-decoration:underline;">Agreement</font><font style="display:inline;font-size:12pt;">&#x201D;) and the Offering Agreement referred to below.</font>
 </p>
 <p style="margin:0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
 <font style="display:inline;font-size:12pt;">&nbsp;</font>
 </p>
 <p style="margin:0pt 0pt 12pt 72pt;text-indent: -72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
 <font style="display:inline;font-size:12pt;">Section 1.<font style="display:inline;font-size:12pt;;font-size: 12pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font></font><font style="display:inline;font-size:12pt;text-decoration:underline;">Engagement</font><font style="display:inline;font-size:12pt;">. The term of the engagement of Roth hereunder will be until the earliest of: (a) 30 days from the date hereof, unless extended by mutual written consent of the Company and Roth; (b) the final consummation of the Offering (as defined below); or (c) earlier termination by the Company as provided below (&#x201C;the </font><font style="display:inline;font-size:12pt;text-decoration:underline;">Engagement Period</font><font style="display:inline;font-size:12pt;">&#x201D;).&nbsp;&nbsp;During the Engagement Period, Roth will serve as the exclusive placement agent or sole book running manager for the Company with respect to one follow-on public offering consisting solely of newly issued shares of common stock and warrants of the Company (such securities, the &#x201C;</font><font style="display:inline;font-size:12pt;text-decoration:underline;">Securities</font><font style="display:inline;font-size:12pt;">&#x201D; and such offering, the &#x201C;</font><font style="display:inline;font-size:12pt;text-decoration:underline;">Offering</font><font style="display:inline;font-size:12pt;">&#x201D;).&nbsp;&nbsp;Notwithstanding the foregoing, the Company may terminate the services of Roth hereunder (x) with cause at any time, and (y) without cause beginning on the 20</font><font style="display:inline;font-size:12pt;font-size:6pt;top:-4pt;position:relative;line-height:100%">th</font><font style="display: